ARTICLE | Company News

Onivyde gains EU approval

October 18, 2016 7:00 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) said the European Commission approved Onivyde irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin to treat metastatic pancreatic cancer in patients who progressed following gemcitabine-based therapy.

Onivyde is approved in the U.S. and Taiwan in the indication (see BioCentury Extra, Oct. 22, 2015). ...